In a 14 to 3 vote, an FDA advisory committee recommended approval of Vantrela ER (Teva), a new hydrocodone bitartrate extended-release tablet with abuse-deterrent capabilities.
Because of the growing epidemic of opioid abuse, misuse and overdose in the United States, the agency has emphasized the importance of developing opioid analgesics with abuse-deterrent capabilities. Teva’s proprietary abuse-deterrent technology for oral tablets is new and unique, according to the